A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (CULMINATE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04023526 |
|
Recruitment Status :
Recruiting
First Posted : July 17, 2019
Last Update Posted : January 31, 2020
|
Sponsor:
Janssen Research & Development, LLC
Collaborator:
argenx BVBA
Information provided by (Responsible Party):
Janssen Research & Development, LLC
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to determine the efficacy of cusatuzumab in combination with azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Leukemia, Myeloid, Acute | Drug: Azacitidine Drug: Cusatuzumab | Phase 2 |
AML is a heterogeneous disease characterized by uncontrolled clonal expansion of hematopoietic progenitor cells. As the most common form of acute leukemia, AML accounts for the largest number of annual deaths from leukemia. Over 95 percent (%) of AML blasts harvested from newly diagnosed AML participants expressed Cluster of Differentiation (CD) 70 on the cell surface. Cusatuzumab (JNJ‑74494550) is a humanized monoclonal antibody of camelid origin, binding with tight affinity to human CD70. Cusatuzumab has been modified to induce enhanced antibodydependent cell-mediated cytotoxicity for therapeutic use in participants with cancer. Azacitidine is a pyrimidine nucleoside analogue of cytidine with antineoplastic activity and is indicated for the treatment of adult participants with AML or intermediate 2 and high-risk myelodysplastic syndrome (MDS) with greater than 20% marrow blasts who are not eligible for hematopoietic stem cell transplantation. This study will evaluate 2 doses of cusatuzumab in combination with standard dose azacitidine in participants with AML who are not candidates for intensive chemotherapy (Part 1). Part 1 data will be reviewed by a Data Review Committee to select a preferred dose of cusatuzumab. Participants will be enrolled into Part 2 at the selected cusatuzumab dose to further evaluate and confirm the response rate, other efficacy endpoints, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD). The study will include a Screening Phase (28 days prior to randomization), a Treatment Phase, and a Follow-up Phase. The study includes evaluations like vital signs, electrocardiogram, spirometry test, serum chemistry and hematology tests. The study will be conducted for an approximate duration of 2 years.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 150 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy |
| Actual Study Start Date : | July 29, 2019 |
| Estimated Primary Completion Date : | December 29, 2020 |
| Estimated Study Completion Date : | April 30, 2021 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Core binding factor acute myeloid leukemia
Cytogenetically normal acute myeloid leukemia
Familial acute myeloid leukemia with mutated CEBPA
Drug Information available for:
Azacitidine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg
Participants will receive azacitidine 75 milligram per meter square (mg/m^2) subcutaneously (SC) or intravenously (IV) on Day 1 through Day 7 and cusatuzumab 10 milligram per kilogram (mg/kg) IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee (DRC) and when a dose of cusatuzumab is selected, randomization will stop and participants will be enrolled into an expansion cohort (Part 2) to evaluate efficacy.
|
Drug: Azacitidine
Azacitidine SC or IV will be administered at a standard dose of 75 mg/m^2 on days 1-7 of each cycle. Drug: Cusatuzumab Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg.
Other Name: JNJ-74494550 |
|
Experimental: Azacitidine 75 mg/m^2 and Cusatuzumab 20 mg/kg
Participants will receive azacitidine 75 mg/m^2 SC or IV on Day 1 through Day 7 and cusatuzumab 20 mg/kg IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a DRC and when a dose of cusatuzumab is selected, randomization will stop and participants will be enrolled into an expansion cohort (Part 2) to evaluate efficacy.
|
Drug: Azacitidine
Azacitidine SC or IV will be administered at a standard dose of 75 mg/m^2 on days 1-7 of each cycle. Drug: Cusatuzumab Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg.
Other Name: JNJ-74494550 |
Primary Outcome Measures :
- Percentage of Participants with Complete Response (CR) [ Time Frame: Up to 1.5 years ]Percentage of participants with complete response based on European Leukemia Network (ELN) 2017 response criteria assessment will be reported.
Secondary Outcome Measures :
- Percentage of Participants with CR with Partial Hematological Recovery (CRh) [ Time Frame: Up to 1.5 years ]Percentage of participants with CRh will be reported based on ELN 2017 response criteria assessment.
- Percentage of Participants with CR plus CRh [ Time Frame: Up to 1.5 years ]Percentage of participants with CR plus CRh will be reported based on ELN 2017 response criteria assessment.
- Percentage of Participants with CR with Incomplete Recovery (CRi) [ Time Frame: Up to 1.5 years ]Percentage of participants with CRi will be reported based on ELN 2017 response criteria assessment.
- Overall Response Rate (ORR) [ Time Frame: Up to 1.5 years ]ORR is defined as percentage of participants with CR, CRh and CRi based on ELN 2017 response criteria assessment.
- Percentage of Participants with CR without MRD [ Time Frame: Up to 1.5 years ]Percentage of participants with CR without minimal residual disease (MRD) will be reported and is defined as less than 1 blast or leukemic stem cell in 1,000 leukocytes (MRD level <10^-3; determined by central lab).
- Percentage of Participants with Negative MRD who Achieved CR, CRh, CRi, or Morphologic Leukemia-free State (MLFS) [ Time Frame: Up to 1.5 years ]Percentage of participants with negative MRD who achieved CR, CRh, CRi, or MLFS will be reported and is defined as less than (<) 1 blast or leukemic stem cell in 1,000 leukocytes (MRD level <10^-3).
- Time to Response [ Time Frame: Up to 1.5 years ]Time to response is defined as time from randomization in Part 1 or enrollment in Part 2 to achieving the first response of CR, CRh, or CRi.
- Duration of Response [ Time Frame: Up to 1.4 years ]Duration of response is defined as time from achieving the first response of CR, CRh, or CRi to disease relapse or death from any cause.
- Red Blood Cell (RBC) or Platelets Transfusion Independence [ Time Frame: Up to 1.5 years ]Transfusion independence (RBC or platelets) is defined as a period of at least 56 consecutive days with no transfusion between first dose of study drug and the last dose of study drug +30 days.
- Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to 1.9 years ]An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
- Minimum Serum Concentration (Cmin) of Cusatuzumab [ Time Frame: Up to 1.9 years ]Cmin is the minimum observed serum concentration.
- Maximum Serum Concentration (Cmax) of Cusatuzumab [ Time Frame: Up to 1.9 years ]Cmax is the maximum observed serum concentration.
- Number of Participants with Anti-cusatuzumab Antibodies [ Time Frame: Up to 1.9 years ]Number of participants exhibiting anti-drug antibodies for cusatuzumab alone and in combination with azacitidine will be reported.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
-
Acute myeloid leukemia (AML) according to World Health Organisation (WHO) 2016 criteria and fulfilling all of the following criteria that defines those who are "not candidates for intensive chemotherapy":
- greater than or equal to (>=)75 years of age or
- less than (<) 75 years of age with at least one of the following comorbidities: Eastern Cooperative Oncology Group (ECOG) Performance Status of 2; Severe cardiac comorbidity defined as congestive heart failure or ejection fraction less than or equal to (<=) 50 percent (%); Severe pulmonary comorbidity defined as documented pulmonary disease with lung diffusing capacity for carbon monoxide (DLCO) <=65% of expected, or forced expiratory volume in 1 second (FEV1) <=65% of expected or dyspnea at rest requiring oxygen; Moderate hepatic impairment defined according to NCI organ dysfunction classification criteria (total bilirubin >=1.5 up to 3 times upper limit of normal [ULN]); Creatinine clearance <45 milliliter per minute per 1.73 meter square (mL/ min/1.73 m^2); Comorbidity that, in the Investigator's opinion, makes the participant unsuitable for intensive chemotherapy and must be documented and approved by the Sponsor before randomization
- De novo or secondary AML
- Previously untreated AML (except: emergency leukapheresis, hydroxyurea, and/or 1 dose of cytarabine [example: 1-2 gram per meter square {g/m^2}] during the Screening Phase to control hyperleukocytosis. These treatments must be discontinued >=24 hours prior to start of study drug). Empiric all trans retinoic acid (ATRA) treatment for presumed acute promyelocytic leukemia (APL) is permitted but APL must be ruled out and ATRA must be discontinued >=24 hours prior to the start of study drug
- Not eligible for an allogeneic hematopoietic stem cell transplantation
- ECOG Performance Status score of 0, 1 or 2
Exclusion Criteria:
- Acute promyelocytic leukemia
- Leukemic involvement or clinical symptoms of leukemic involvement of the central nervous system
- Use of immune suppressive agents for the past 4 weeks before the first administration of cusatuzumab on Cycle 1 Day 3. For regular use of systemic corticosteroids, participants may only be included if free of systemic corticosteroids for a minimum of 5 days before the first administration of cusatuzumab. Treatment of adrenal insufficiency with physiologic replacement doses of corticosteroids are allowed
- Prior treatment with a hypomethylating agent for treatment of AML or myelodysplastic syndrome (MDS)
- Active malignancies (that is, progressing or requiring treatment in the last 24 months) other than the disease being treated under the study
- Any active systemic infection
- Known allergies, hypersensitivity, or intolerance to cusatuzumab or azacitidine or its excipients (that is, mannitol, an excipient of azacitidine)
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04023526
Contacts
| Contact: Study Contact | 844-434-4210 | JNJ.CT@sylogent.com |
Locations
Show 62 study locations
Sponsors and Collaborators
Janssen Research & Development, LLC
argenx BVBA
Investigators
| Study Director: | Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC |
Additional Information:
| Responsible Party: | Janssen Research & Development, LLC |
| ClinicalTrials.gov Identifier: | NCT04023526 |
| Other Study ID Numbers: |
CR108609 2019-000473-23 ( EudraCT Number ) 74494550AML2001 ( Other Identifier: Janssen Research & Development, LLC ) |
| First Posted: | July 17, 2019 Key Record Dates |
| Last Update Posted: | January 31, 2020 |
| Last Verified: | January 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu |
| URL: | https://www.janssen.com/clinical-trials/transparency |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | Yes |
Additional relevant MeSH terms:
|
Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms by Histologic Type Neoplasms Azacitidine |
Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Enzyme Inhibitors |